- Home
- EVN vs TECX Comparison
EVN vs TECX Comparison
Compare EVN & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVN
- TECX
- Stock Information
- Founded
- EVN 1998
- TECX 2019
- Country
- EVN United States
- TECX United States
- Employees
- EVN N/A
- TECX N/A
- Industry
- EVN Investment Bankers/Brokers/Service
- TECX
- Sector
- EVN Finance
- TECX
- Exchange
- EVN Nasdaq
- TECX Nasdaq
- Market Cap
- EVN 410.0M
- TECX 334.4M
- IPO Year
- EVN N/A
- TECX 2018
- Fundamental
- Price
- EVN $10.37
- TECX $21.69
- Analyst Decision
- EVN
- TECX Buy
- Analyst Count
- EVN 0
- TECX 6
- Target Price
- EVN N/A
- TECX $78.67
- AVG Volume (30 Days)
- EVN 101.2K
- TECX 241.7K
- Earning Date
- EVN 01-01-0001
- TECX 08-13-2025
- Dividend Yield
- EVN 4.78%
- TECX N/A
- EPS Growth
- EVN N/A
- TECX N/A
- EPS
- EVN 0.34
- TECX N/A
- Revenue
- EVN N/A
- TECX N/A
- Revenue This Year
- EVN N/A
- TECX N/A
- Revenue Next Year
- EVN N/A
- TECX N/A
- P/E Ratio
- EVN $29.94
- TECX N/A
- Revenue Growth
- EVN N/A
- TECX N/A
- 52 Week Low
- EVN $8.64
- TECX $13.70
- 52 Week High
- EVN $10.45
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- EVN 61.22
- TECX 51.82
- Support Level
- EVN $10.23
- TECX $19.13
- Resistance Level
- EVN $10.27
- TECX $21.46
- Average True Range (ATR)
- EVN 0.06
- TECX 1.27
- MACD
- EVN 0.02
- TECX -0.00
- Stochastic Oscillator
- EVN 73.08
- TECX 70.50
About EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.